StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.86−0.10 (-2.53%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Artiva Biotherapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Artiva Biotherapeutics's profit margin for the twelve months ending Dec 31, 2024 was -26045.0%. For fiscal 2024 it was -26045.0%, against -85.8% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2024Dec 31, 2024-26045.0%−25959.3
FY2023Dec 31, 2023-85.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2024Mar 31, 2024-5562.9%–
Q4 FY2023Dec 31, 2023-510.6%–
Q3 FY2023Sep 30, 202342.3%–
Q2 FY2023Jun 30, 2023-322.7%–

More Artiva Biotherapeutics figures

See a number that looks wrong?